Related Experiment Videos
Interstitial lung diseases--where we started from and are now going
Herbert Y Reynolds1, Dorothy B Gail, James P Kiley
1Division of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD, USA. reynoldh@nhlbi.nih.gov
Summary
Interstitial lung diseases (ILD) research, particularly idiopathic pulmonary fibrosis (IPF), has evolved from immunology to focus on alveolar injury and fibrogenesis. Current NHLBI programs aim for new therapies and genetic factors in IPF.
Area of Science:
- Pulmonary Medicine
- Immunology
- Fibrotic Lung Diseases
Background:
- Interstitial lung diseases (ILD) research initiated 35 years ago, driven by advancements in cellular immunology and airway sampling techniques.
- The National Heart and Lung Institute prioritized fibrotic and immunologic lung diseases in 1972, leading to dedicated research programs.
- This review highlights early research on idiopathic pulmonary fibrosis (IPF) from the Pulmonary Branch.
Purpose of the Study:
- To review the historical development of interstitial lung diseases (ILD) research.
- To focus on the evolution of research paradigms in idiopathic pulmonary fibrosis (IPF).
- To outline current and future research directions supported by the National Heart, Lung, and Blood Institute (NHLBI).
Main Methods:
- Historical review of research programs and funding initiatives.
- Analysis of shifts in research focus from inflammation to cellular injury and fibrogenesis.
- Examination of therapeutic strategies and their effectiveness.
Main Results:
- Research emphasis shifted in the 1990s from inflammation to alveolar epithelial injury, fibrogenesis, and matrix remodeling.
- More precise classification of ILD, especially IPF, was advocated.
- Therapeutic strategies, including anti-fibrotic agents and interferon gamma, showed limited efficacy.
Conclusions:
- Despite progress, current therapies for IPF remain insufficient.
- NHLBI continues to support ILD research, focusing on new molecular targets and therapeutic combinations.
- Future directions include identifying genetic susceptibility factors and establishing bio-repositories for IPF research.